Compounds > 1,2-di-(heptacosadiynoyl)-sn-glycero-3-phosphocholine
Page last updated: 2024-12-10
1,2-di-(heptacosadiynoyl)-sn-glycero-3-phosphocholine
Description
## 1,2-di-(heptacosadiynoyl)-sn-glycero-3-phosphocholine (Di-heptacosadiynoyl-PC)
This is a complex chemical name referring to a specific type of **phospholipid**. Let's break it down:
* **1,2-di-(heptacosadiynoyl)-:** This part describes the fatty acid chains attached to the glycerol backbone.
* **Heptacosadiynoyl:** This is a 27-carbon long fatty acid containing two triple bonds (indicated by di-ynoyl).
* **1,2-di-:** This indicates that two of these heptacosadiynoyl chains are attached to the first and second carbon positions of the glycerol molecule.
* **sn-glycero-3-phospho:** This part refers to the glycerol backbone with a phosphate group attached to the third carbon.
* **choline:** This is the head group of the phospholipid, attached to the phosphate group.
**In summary, Di-heptacosadiynoyl-PC is a phospholipid with two long, unsaturated fatty acid chains and a choline head group.**
## Importance in Research
Di-heptacosadiynoyl-PC is a very specific type of phospholipid that is **not found naturally**. It's important for research because it has several unique properties that make it a valuable tool for studying:
* **Membrane structure and dynamics:** Di-heptacosadiynoyl-PC's rigid structure and long fatty acid chains allow researchers to manipulate and study the physical properties of cell membranes, like fluidity and permeability.
* **Lipid signaling:** The unique structure of the fatty acid chains can influence how cells respond to various stimuli, providing insights into lipid signaling pathways.
* **Drug delivery:** The hydrophobic nature of the fatty acid chains makes Di-heptacosadiynoyl-PC a potential carrier for drugs that need to be delivered across cell membranes.
* **Biomaterial development:** The unique properties of this phospholipid can be utilized in the development of novel biomaterials for tissue engineering and drug delivery.
**In essence, Di-heptacosadiynoyl-PC serves as a model system for studying the role of phospholipids in biological systems. By altering its structure and properties, researchers can gain valuable insights into the mechanisms of cellular function and develop novel applications for this synthetic phospholipid.**
1,2-di-(heptacosadiynoyl)-sn-glycero-3-phosphocholine: RN given refers to (11,13-diyn)-isomer; RN for cpd without isomeric designation 8/89 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
PubMed CID | 3081146 |
SCHEMBL ID | 9805716 |
MeSH ID | M0160108 |
Synonyms (7)
Synonym |
1,2-di-(heptacosadiynoyl)-sn-glycero-3-phosphocholine |
118024-74-1 |
3,5,9-trioxa-4-phosphahexatriaconta-20,22-diyn-1-aminium, 4-hydroxy-n,n,n-trimethyl-10-oxo-7-((1-oxo-11,13-heptacosadiynyl)oxy)-, hydroxide, inner salt, 4-oxide, (r)- |
dc8,9pc |
[(2r)-2,3-di(heptacosa-11,13-diynoyloxy)propyl] 2-(trimethylazaniumyl)ethyl phosphate |
SCHEMBL9805716 |
DTXSID90152002 |
Research
Studies (7)
Timeframe | Studies, This Drug (%) | All Drugs % |
pre-1990 | 1 (14.29) | 18.7374 |
1990's | 1 (14.29) | 18.2507 |
2000's | 3 (42.86) | 29.6817 |
2010's | 2 (28.57) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.66
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
Metric | This Compound (vs All) |
---|
Research Demand Index | 12.66 (24.57) | Research Supply Index | 2.08 (2.92) | Research Growth Index | 4.73 (4.65) | Search Engine Demand Index | 0.00 (26.88) | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 7 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |